Pipeline

Edge is working with researchers around the world to develop a rich pipeline of drugs targeting conditions such as brain hemorrhage, TBI and Brain Surgery.

Edge is overcoming current treatment shortcomings with its proprietary site-specific sustained release microparticle platform technology.  This allows delivery of medications directly to the brain during standard brain surgery or via minimally invasive techniques and then releasing the active drug over a period of time. This approach allows Edge’s products to achieve therapeutic concentrations of medicine at the site of brain injury without causing side effects in other parts of the body. Edge has four hospital products with multiple applications in the pipeline that address various secondary complications following bleeding in the brain.

NimoGel and NimoVent, Edge’s lead products, are being developed to prevent delayed cerebral ischemia, a catastrophic delayed complication after subarachnoid hemorrhage (SAH). NimoGel and NimoVent contain the known active calcium channel blocker nimodipine, formulated in a biodegradable polymer carrier composed of FDA-approved materials. Specifically, NimoGel and NimoVent are a combination of the widely used validated drug with a proven, proprietary, GRAS-designated, sustained-release formulation.